Becotatug vedotin plus immunotherapy for head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed head and neck squamous cell carcinoma (in mouth, throat, or voice box) that hasn't been treated before
- Tumor must be EGFR-positive and have a CPS score of 1 or higher (special markers showing the cancer may respond to treatment)
- Surgeon determines you are healthy enough for curative surgery
- Age 18–75 years with good overall health (ECOG score 0–1, meaning you can do most daily activities)
- Normal blood counts, liver, kidney, and heart function (based on lab tests and heart imaging)
- Able to use contraception during and 3 months after treatment if of childbearing age
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This study tests two medications given before surgery to shrink mouth cancer and improve outcomes. It is for people with a certain type of mouth cancer that has not been treated yet and can be removed with surgery.
This trial tests a new drug combo—becotatug vedotin plus a PD-1 inhibitor—for people with head and neck squamous cell cancer that cannot be surgically removed. It aims to see if this treatment can shrink tumors or slow their growth.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.